Learn about the complexity of rare disease and the unique difficulty it presents to patients and families by exploring the patient journey—from diagnosis to research to drug development.

A JAX-led study of more than 5,000 people is challenging long-held assumptions about cerebral palsy genetics.

Genomics in Action learning path brings applied science, career exploration, and workforce-ready skills to community college students.

YouTube video by The Jackson Laboratory

How JAX scientists are investigating whether our skin microbiome could serve as a window into the biology of aging and frailty.

Supported by an ASAP Collaborative Research Network grant, JAX-NYSCF researchers will create, validate, and share human stem cell models and data for emerging Parkinson’s disease targets.

By studying how cells are born, integrate, and regenerate, JAX researchers are uncovering the foundations of human health.

Understanding the brain to change the future of human health.

JAX scientists are advancing genetic and genomic research to uncover the mechanisms of disease and accelerate precision medicine.

By studying how cancer begins, evolves, and responds to treatment, JAX researchers are opening new paths to earlier detection, and improved patient outcomes.

JAX researchers are working to understand the biological mechanisms that allow some individuals to remain healthier longer.

Mistry et al. propose that Dnmt3a-mutant haematopoietic cells induce mesenchymal stromal cell senescence. Removal of senescent non-haematopoietic cells reduces Dnmt3a-mutant haematopoiesis.

Through a new partnership with The France Foundation, JAX is broadening continuing education and strengthening collaborative care nationwide.

By automating one of biology's most labor-intensive processes, a robotic platform is helping scientists grow and study organoids for diabetes and other complex diseases at unprecedented scale.

By automating one of biology's most labor-intensive processes, a robotic platform is helping scientists grow and study organoids for diabetes and other complex diseases at unprecedented scale.

A new nonprofit wants to streamline gene therapy for diseases often avoided by pharmaceutical companies — making treatment more like a routine procedure than a bespoke drug.

A new collaboration to develop precision medicines for those with rare diseases, using infrastructure and repeatable practices that will be shared with others.

Extracting fine-grained movement and posture data, the tool creates behavior annotations and disease metrics linked to genetics, models, and drug responses.

Twelve organizations spanning gene editing science, clinical medicine, manufacturing, regulatory strategy, and patient advocacy aim to deliver first-in-human trial within three years. div.hero-section...

Pediatric Epilepsies & Rare CNS Gene Editing Platform (PERC) accelerates the development of precision genetic medicines for severe childhood neurologic disease.

YouTube video by The Jackson Laboratory